CynosBio, Inc. is a regenerative medicine company developing and commercializing tissue-engineered, autologous cell therapies that have been clinically validated in Japan and are being advanced toward global development. 

Headquartered in Tokyo (Nihonbashi), CynosBio conducts its clinical development activities in Japan, with CMC development and GMP/GCTP manufacturing based in Kobe Port Island, one of Japan’s leading biomedical clusters. 

We focus on tissue-engineered cell therapies designed to regenerate functional tissues using three-dimensional culture systems, rather than simple cell expansion. 

Our core programs include Sakracy®, an epithelial cell-sheet therapy for ocular surface reconstruction, and IK-01, an autologous cartilage-derived cell therapy for knee cartilage repair. 

CynosBio integrates clinical development, manufacturing strategy, and quality systems to advance regenerative medicine products from research to real-world clinical use, and actively collaborates with academic, clinical, and regulatory partners to pursue global development opportunities.

CynosBio, Inc.

Org chart

Teams

Offices

CynosBio, Inc.

Org chart

Teams

Offices

Related companies